Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, in overweight and obese patients. This Phase 2 study successfully characterized patients who responded best to treatment and also provided important information to inform dose selection.

At 28 weeks, evaluable patients with a starting body mass index (BMI) less than 35 kg/m2 (n=149), and treated with the highest pramlintide/metreleptin doses, experienced significantly more weight loss on average (11%; 22 pounds, p<0.01) than those receiving placebo (1.8%; 4 pounds) or either agent alone (approximately 5%; 10 pounds). Consistent with the physiologic role of leptin in regulating body fat, the weight loss in these patients was predominantly due to a reduction in fat mass (approximately 18 of the 22 pounds lost). These study results confirm previous Phase 2 results with this combination therapy and provide a solid foundation for the Company's ongoing obesity development program.

In the overall evaluable study population, all of the pramlintide/metreleptin combination arms achieved more weight loss than placebo. The magnitude of weight loss was found to be dependent on dosage and baseline BMI. In a pre-specified analysis of evaluable patients with a starting BMI less than 35 kg/m2, weight loss with pramlintide/metreleptin was more than additive compared to that with pramlintide and metreleptin alone, a finding that was not observed in the overall evaluable population.

"Despite their best efforts with diet and exercise alone, most overweight or obese individuals experience progressive weight
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...   BioTE Medical , a leading provider ... pellets, today announced the addition of Dr. ... Rouzier is joining the BioTE Medical Advisory Board ... Rouzier was residency trained in Family Medicine and ... certified emergency physician still practicing at a large ...
(Date:7/22/2014)... 2014 CTD Holdings, Inc. (OTCQB:CTDH), a ... device, cosmetics, and other markets, announced today that it ... of qualified private investors led by Novit L.P., an ... The transaction involved the signing of a Securities Purchase ... Common Stock at a price per share of $1.00, ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 ... attendance at the 2014 NCSL International Workshop and ... #423 will feature CONDEC pressure instrumentation, OIML M1 ... and the new, customized sets, Essential Weights™. , ... promote cooperative efforts in solving the common problems ...
(Date:7/22/2014)... Two new members were elected to ... its annual Shareholders Meeting on June 13: Kerry R. ... PFM Group, and Stephen T. Zarrilli, President and CEO ... election of Michael A. DiPiano, Managing General Partner of ... P. Jaffe, Esq., of Duane Morris LLP, as Director ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2Two New Members Elected to University City Science Center Board of Directors 2Two New Members Elected to University City Science Center Board of Directors 3
... Dr. Kyong S. Choe, of Kwangju, South Korea, has been ... outstanding contributions and achievements in the field of healthcare. ... Dr. Choe is currently practicing with Feldman, Fitzgerald ... periodontics and prosthodontics targeting implants and full prosthetic reconstruction.  He ...
... on Tel Aviv Stock Exchange. - Common Stock to List on both Tel ... the Ticker Symbol PLX -,- Company Anticipates Joining TASE,s TA-75, TA-100, Tel-Tech, Tel-Tech ... to Dual List on Tel Aviv Stock Exchange -- CARMIEL, Israel, Aug. 30 ... ...
... August 30, 2010 ... if ... var shortURL = ""; BitlyCB.alertResponse = ... to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
Cached Biology Technology:Dr. Kyong S. Choe Recognized by Strathmore's Who's Who Worldwide Publication 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 3Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 4Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 5Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 6Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 7Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 2Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 3Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 4Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 5Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 6Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 7Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 9
(Date:7/22/2014)... chances are you are), help may be on the ... developed a vaccine that can combat dust-mite allergies by ... the nano-sized vaccine package lowered lung inflammation by 83 ... the paper, published in the AAPS (American ... reason why it works, the researchers contend, is because ...
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... cost-effectiveness analysis of commercial diet programs and pills, the ... best value for the money. The Jenny Craig regimen ... most expensive option tested, according to researchers at Duke-National ... findings, published in the June issue of the journal ... and weight-loss benefits per dollar spent as insurance carriers ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3
... New discoveries by researchers at the University ... a first-ever pharmacological treatment for cocaine addiction. ... to treat people with hypertension and anxiety, has ... from retrieving memories associated with cocaine use in ...
... , STONY BROOK, NY"Trophic Downgrading of Planet Earth," a review ... the journal Science, concludes that the decline of ... is causing substantial changes to Earth,s terrestrial, freshwater, and marine ... from ecosystems "may be humankind,s most pervasive influence on nature." ...
... achieved a pivotal breakthrough in the development of a cable ... possible. Armchair quantum wire (AQW) will be a weave ... over long distances. It will be an ideal replacement for ... 5 percent per 100 miles of transmission, said Rice chemist ...
Cached Biology News:UWM research offers hope for treatment of cocaine addiction 2Loss of top animal predators has massive ecological effects 2Loss of top animal predators has massive ecological effects 3'Amplified' nanotubes may power the future 2'Amplified' nanotubes may power the future 3
SHP-2 Antibody...
Anti human PPAR gamma2 mouse monoclonal antibody...
... The antiserum has been tested on tissue ... staining pattern obtained with AB1773 corresponds to ... with probes to GLYT2 mRNA and to ... Preabsorption of the antiserum with the immunogen ...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
Biology Products: